73 episodes

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, and regulatory challenges you’ll face as you navigate your company from an idea to success in the clinic. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by BioProcess Online and brought to you by Cytiva, formerly GE Healthcare Life Sciences.

Business Of Biotech Matt Pillar

    • Business
    • 4.9 • 33 Ratings

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, and regulatory challenges you’ll face as you navigate your company from an idea to success in the clinic. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by BioProcess Online and brought to you by Cytiva, formerly GE Healthcare Life Sciences.

    Democratizing Biologics With Lumen Bioscience's Brian Finrow, J.D. & Craig Behnke, Ph.D.

    Democratizing Biologics With Lumen Bioscience's Brian Finrow, J.D. & Craig Behnke, Ph.D.

    Making powerful and curative biologic therapies accessible to patients from all walks of life, and all corners of the globe, requires radically innovative thinking. On this episode of the Business of Biotech, Lumen Bioscience's Co-Founder and CEO Brian Finrow, J.D. and EVP of Production/Development Craig Behnke, Ph.D. discuss a novel approach: developing therapeutic proteins from readily-available food algae spirulina. It's driving a diverse pipeline of candidates into the clinic, for indications reaching from the gut to the heart and lungs.  

    • 49 min
    Cornering The Antibody Market With Akesobio CEO Dr. Michelle Xia, Ph.D.

    Cornering The Antibody Market With Akesobio CEO Dr. Michelle Xia, Ph.D.

    In business for just a decade, Akesobio's stats are mindboggling: 20 drug development programs, including 12 antibodies in clinical-stage development, six bi-specific antibodies (two at clinical stage),  four antibodies with IND approvals from the FDA, and 22 clinical trials initiated. The company's CEO, Michelle Xia, Ph.D., sat down with the Business of Biotech for a conversation about how the company has managed such supercharged growth.

    • 48 min
    Turning The Liver Into A mAb Factory With Homology's Arthur Tzianabos, Ph.D.

    Turning The Liver Into A mAb Factory With Homology's Arthur Tzianabos, Ph.D.

    Homology Medicines' approaches to gene therapy and gene editing have the potential to seriously disrupt both the cell/gene therapy space and the mAb manufacturing and administration paradigms as we know them. On this episode of the Business of Biotech, Homology President & CEO Arthur Tzianabos, Ph.D. shares the company's approach and supports its rationale for investing in its own development and manufacturing capacity. 

    • 50 min
    Maximizing mRNA With Precision Nanosystems' James Taylor, Ph.D.

    Maximizing mRNA With Precision Nanosystems' James Taylor, Ph.D.

    Dr. James Taylor believes that genomic medicine will prove the most revolutionary thing the life sciences industries have ever seen, and that it will ultimately become the largest therapeutic class. Dr. Taylor is president an CEO at Precision Nanosystems. He chalks up the genomic nature of biology, the fact that genomes are information-based,  the breadth and validation of the genomic medicine toolbox, and the democratization of genomic medicine development as reasons to be bullish. Join Dr. Taylor and me for a conversation on why RNA and DNA delivery are game-changers, and what Precision Nanosystems is doing to push the ball downfield.  

    • 41 min
    Foundations Of Flexible Manufacturing With Sarepta Therapeutics' Brian Winstead

    Foundations Of Flexible Manufacturing With Sarepta Therapeutics' Brian Winstead

    Is "flexible manufacturing" just another empty buzz concept concocted by the biopharma equipment marketing community, or does it demonstrate real benefit to bioprocess pros and their companies? On this episode, we sit down with Sarepta Therapeutics Director of Pharmaceutical Engineering Brian Winstead and Project Farma VP Tony Khoury to discuss what flexible manufacturing means, where it works, and where it doesn't. Listen in as Winstead shares the flexible manufacturing philosophy at Sarepta. 

    • 55 min
    The CDMO Capacity Crunch With Discovery Labs' Audrey Greenberg and Iovance Biotherapeutics' Sumit Verma

    The CDMO Capacity Crunch With Discovery Labs' Audrey Greenberg and Iovance Biotherapeutics' Sumit Verma

    While nary a day goes by without a shovel breaking ground on a new CDMO buildout, biopharmas remain hard-pressed to secure the outsourced manufacturing space and expertise needed to meet timelines, satisfy investors, and drive competitive advantage. On this episode of the Business of Biotech, we're tackling the CDMO capacity crunch from every angle in a spirited discussion with Discovery Labs & Center for Breakthrough Medicines Co-Founder Audrey Greenberg, Iovance SVP of Commercial Manufacturing Sumit Verma, and Project Farma CEO Anshul Mangal.

    • 48 min

Customer Reviews

4.9 out of 5
33 Ratings

33 Ratings

SDSU.aztecs ,

Great Podcast for Biotech Prossionals

Found this podcast as I prepared for a position with a big Pharma company and found Matt’s interviews to shed light on some of the strategies and tactics of the professionals/ firms in the field. Great way to understand how science is and can be accomplished beyond the scientific headlines and papers.

Top Podcasts In Business

You Might Also Like